-
1.发明授权公开(公告)号：US10682624B2
公开(公告)日：2020-06-16
申请号：US16238443
申请日：2019-01-02
申请人： IMMUNOLIGHT, LLC. , DUKE UNIVERSITY
IPC分类号： B01J19/12 , A23L3/26 , A61L2/00 , C02F1/30 , C02F1/72 , A23L5/30 , B01J19/08 , A61L2/08 , A61L2/10 , A61L2/16 , C08J3/28 , G21K5/00 , C02F1/32 , A61K41/00 , A61N5/06 , A61N5/10 , B01J23/50 , B01J23/52 , B01J31/02 , B01J31/22 , B01J35/00 , B01J37/00 , B01J37/02 , C09D201/00 , C09J5/00 , C09J201/00 , A23L2/50 , A23L3/28 , C08J3/24 , C08J7/18 , G02B5/00 , A61M1/36 , C12H1/06 , B82Y20/00 , B82Y30/00 , B82Y40/00
摘要： A method and a system for producing a change in a medium disposed in an artificial container. The method places in a vicinity of the medium at least one of a plasmonics agent and an energy modulation agent. The method applies an initiation energy through the artificial container to the medium. The initiation energy interacts with the plasmonics agent or the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the plasmonics agent or the energy modulation agent.
-
公开(公告)号：US09526914B2
公开(公告)日：2016-12-27
申请号：US14716394
申请日：2015-05-19
申请人： IMMUNOLIGHT, LLC , DUKE UNIVERSITY
发明人： Tuan Vo-Dinh , Jonathan P. Scaffidi , Venkata Gopal Reddy Chada , Benoit Lauly , Yan Zhang , Molly K. Gregas , Ian Nicholas Stanton , Joshua T. Stecher , Michael J. Therien , Frederic A. Bourke, Jr. , Harold Walder , Zak Fathi , Jennifer A. Ayres , Zhenyuan Zhang , Joseph H. Simmons , Stephen John Norton
CPC分类号： A61N5/062 , A61B5/0059 , A61B5/0071 , A61B5/055 , A61B5/4848 , A61B6/481 , A61K41/0042 , A61K41/0052 , A61K41/0061 , A61K49/0039 , A61L2/0047 , A61L2/08 , A61L2202/21 , A61L2202/22 , A61M5/007 , A61N1/406 , A61N5/02 , A61N5/0601 , A61N5/0618 , A61N5/0622 , A61N5/0624 , A61N5/10 , A61N2005/063 , A61N2005/0656 , A61N2005/0659 , A61N2005/0662 , A61N2005/067 , A61N2005/1098
摘要： Products, compositions, systems, and methods for modifying a target structure. The methods may be performed in a non-invasive manner by placing a nanoparticle having a metallic shell on at least a fraction of a surface in a vicinity of a target structure in a subject and applying an initiation energy thus producing an effect on or change to the target structure directly or via a modulation agent. The nanoparticle is configured, upon exposure to a first wavelength λ1, to generate a second wavelength λ2 of radiation having a higher energy than the first wavelength λ1. The methods may further be performed by application of an initiation energy to activate a photoactivatable agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure.
摘要翻译： 用于修改目标结构的产品，组成，系统和方法。 所述方法可以以非侵入性方式进行，通过将具有金属壳的纳米颗粒放置在受试者的靶结构附近的表面的至少一部分上，并施加引发能量，从而产生作用或改变 目标结构直接或通过调制剂。 纳米颗粒在暴露于第一波长λ1时被配置为产生具有比第一波长λ1更高的能量的辐射的第二波长λ2。 所述方法还可以通过施加起始能量来直接地或经由能量调节剂，任选地在一种或多种等离子体激元活性剂的存在下活化可光活化剂，从而对目标结构产生影响或改变。
-
公开(公告)号：US11992697B2
公开(公告)日：2024-05-28
申请号：US17655683
申请日：2022-03-21
申请人： IMMUNOLIGHT, LLC , DUKE UNIVERSITY
发明人： Mark Oldham , Zakaryae Fathi , Wayne F. Beyer , Frederic A. Bourke, Jr. , Harold Walder , Mark Dewhirst , Neil L. Spector , Paul Yoon , Justus Adamson , David Alcorta , Kim Lyerly , Leihua Liu , Takuya Osada
IPC分类号： A61N5/06 , A61K31/352 , A61K41/00 , A61N5/10
CPC分类号： A61N5/062 , A61K31/352 , A61K41/0066 , A61N2005/0661 , A61N2005/0662 , A61N5/10 , A61N2005/1089 , A61N2005/1098
摘要： A method for treating a diseased site in a human or animal body is provided which includes injecting in a diseased site one or more phosphors which are capable of emitting ultraviolet or visible light into the body;
infusing the diseased site with a photoactivatable drug;
applying an initiation energy from an initiation energy source comprising an x-ray, gamma ray, or electron source to thereby initiate emission of ultraviolet or visible light into the body; and
controlling a dose of the initiation energy with a processor to produce (i) a cytotoxicity inside the diseased site of greater than 20% or (ii) a day-25 stable tumor volume,
wherein the processor is programmed to apply the initiation energy in a pulsed manner, wherein the initiation energy is delivered in either (i) a radiograph mode, or (ii) a pulsed fluoroscopy mode.-
公开(公告)号：US11786595B2
公开(公告)日：2023-10-17
申请号：US17227753
申请日：2021-04-12
申请人： IMMUNOLIGHT, LLC , DUKE UNIVERSITY
发明人： Mark Oldham , Justus Adamson , Mark W. Dewhirst , Paul Yoon , Harold Walder , Frederic A. Bourke, Jr. , Zakaryae Fathi , Wayne F. Beyer, Jr.
IPC分类号： A61K41/00 , A61N5/06 , A61K31/655 , A61K33/02 , A61K31/409 , A61K31/525 , A61K31/352 , A61K31/403 , A61K33/242 , A61K33/244 , A61K33/24 , A61N5/10 , A61K31/426 , A61K31/47 , B82Y5/00
CPC分类号： A61K41/0066 , A61K31/352 , A61K31/403 , A61K31/409 , A61K31/525 , A61K31/655 , A61K33/02 , A61K33/24 , A61K33/242 , A61K33/244 , A61N5/062 , A61N5/0624 , A61N5/10 , A61K31/426 , A61K31/47 , A61K2300/00 , A61N2005/065 , A61N2005/1095 , A61N2005/1098 , B82Y5/00 , Y02A50/30
摘要： A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.
-
公开(公告)号：US11589432B2
公开(公告)日：2023-02-21
申请号：US16012901
申请日：2018-06-20
申请人： IMMUNOLIGHT, LLC. , DUKE UNIVERSITY
发明人： Frederic A. Bourke, Jr. , Zakaryae Fathi , Ian Nicholas Stanton , Michael J. Therien , Paul Rath Stauffer , Paolo Maccarini , Katherine Sarah Hansen , Diane Renee Fels , Cory Robert Wyatt
摘要： Methods and systems for producing a change in a medium. A first method and system (1) place in a vicinity of the medium at least one upconverter including a gas for plasma ignition, with the upconverter being configured, upon exposure to initiation energy, to generate light for emission into the medium, and (2) apply the initiation energy from an energy source including the first wavelength λ1 to the medium, wherein the emitted light directly or indirectly produces the change in the medium. A second method and system (1) place in a vicinity of the medium an agent receptive to microwave radiation or radiofrequency radiation, and (2) apply as an initiation energy the microwave radiation or radiofrequency radiation by which the agent directly or indirectly generates emitted light in the infrared, visible, or ultraviolet range to produce at least one of physical and biological changes in the medium.
-
6.发明授权公开(公告)号：US11278861B2
公开(公告)日：2022-03-22
申请号：US16900091
申请日：2020-06-12
申请人： IMMUNOLIGHT, LLC , DUKE UNIVERSITY
IPC分类号： B01J19/12 , A23L3/26 , A61L2/00 , C02F1/30 , C02F1/72 , A23L5/30 , B01J19/08 , A61L2/08 , A61L2/10 , A61L2/16 , C08J3/28 , G21K5/00 , C02F1/32 , A61K41/00 , A61N5/06 , A61N5/10 , B01J23/50 , B01J23/52 , B01J31/02 , B01J31/22 , B01J35/00 , B01J37/00 , B01J37/02 , C09D201/00 , C09J5/00 , C09J201/00 , A23L2/50 , A23L3/28 , C08J3/24 , C08J7/18 , G02B5/00 , A61M1/36 , C12H1/06 , B82Y20/00 , B82Y30/00 , B82Y40/00
摘要： A method and a system for producing a change in a medium disposed in an artificial container. The method places in a vicinity of the medium at least one of a plasmonics agent and an energy modulation agent. The method applies an initiation energy through the artificial container to the medium. The initiation energy interacts with the plasmonics agent or the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the plasmonics agent or the energy modulation agent.
-
公开(公告)号：US10940329B2
公开(公告)日：2021-03-09
申请号：US15819130
申请日：2017-11-21
申请人： IMMUNOLIGHT, LLC , DUKE UNIVERSITY
发明人： Mark Oldham , Justus Adamson , Paul Yoon , Harold Walder , Frederic A. Bourke, Jr. , Zakaryae Fathi , Wayne F. Beyer
IPC分类号： A61K49/00 , A61N5/10 , C09K11/59 , C09K11/73 , C09K11/02 , A61K31/37 , A61P35/00 , A61K41/00 , A61K49/04
摘要： A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug.
-
公开(公告)号：US10441810B2
公开(公告)日：2019-10-15
申请号：US15434871
申请日：2017-02-16
申请人： IMMUNOLIGHT, LLC , DUKE UNIVERSITY
发明人： Mark Oldham , Zakaryae Fathi , Wayne F. Beyer , Harold Walder , Frederic A. Bourke, Jr. , Mark Dewhirst , Neil L. Spector , Paul Yoon , Justus Adamson , David Alcorta , Kim Lyerly , Leihua Liu , Takuya Osada
IPC分类号： A61N5/06 , A61K41/00 , A61N5/10 , A61K31/352
摘要： A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.
-
公开(公告)号：US09283275B2
公开(公告)日：2016-03-15
申请号：US14573511
申请日：2014-12-17
申请人： Duke University , Immunolight, LLC
CPC分类号： A61K41/0061 , A61K9/14 , A61K9/143 , A61K31/37 , A61K39/00 , A61K41/0028 , A61K41/0066 , A61K47/52 , A61K2039/57 , A61N5/06 , A61N5/062
摘要： The use of plasmonics enhanced photospectral therapy (PEPST) and exiton-plasmon enhanced phototherapy (EPEP) in the treatment of various cell proliferation disorders, and the PEPST and EPEP agents and probes used therein.
-
公开(公告)号：US11383098B2
公开(公告)日：2022-07-12
申请号：US16516463
申请日：2019-07-19
申请人： Immunolight, LLC , Duke University
发明人： Tuan Vo-Dinh , Jonathan P. Scaffidi , Venkata Gopal Reddy Chada , Benoit Lauly , Yan Zhang , Molly K. Gregas , Ian Nicholas Stanton , Joshua T. Stecher , Michael J. Therien , Frederic A. Bourke, Jr. , Harold Walder , Zak Fathi , Jennifer A. Ayres , Zhenyuan Zhang , Joseph H. Simmons , Stephen John Norton
IPC分类号： A61N5/06 , A61K49/00 , A61N1/40 , A61N5/02 , A61B5/00 , A61B5/055 , A61B6/00 , A61K41/00 , A61M5/00 , A61L2/00 , A61L2/08 , A61N5/067 , A61N5/10
摘要： Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by placing a nanoparticle having a metallic shell on at least a fraction of a surface in a vicinity of a target structure in a subject and applying an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The nanoparticle is configured, upon exposure to a first wavelength λ1, to generate a second wavelength λ2 of radiation having a higher energy than the first wavelength λ1. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.
-
-
-
-
-
-
-
-
-
搜索结果
71 条记录 (耗时 0.029 秒)
